# A Study to Evaluate the Efficacy and Safety of CREZET Tablet

> **NCT05889143** · — · ACTIVE_NOT_RECRUITING · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 15000 (estimated)

## Conditions studied

- Dyslipidemias

## Interventions

- **DRUG:** Ezetimibe/Rosuvastatin

## Key facts

- **NCT ID:** NCT05889143
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-24
- **Primary completion:** 2024-12-31
- **Final completion:** 2026-03-01
- **Target enrollment:** 15000 (ESTIMATED)
- **Last updated:** 2025-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05889143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05889143, "A Study to Evaluate the Efficacy and Safety of CREZET Tablet". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05889143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*